|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NBAS |
Gene summary for NBAS |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NBAS | Gene ID | 51594 |
| Gene name | NBAS subunit of NRZ tethering complex | |
| Gene Alias | ILFS2 | |
| Cytomap | 2p24.3 | |
| Gene Type | protein-coding | GO ID | GO:0000184 | UniProtAcc | A2RRP1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51594 | NBAS | CCI_2 | Human | Cervix | CC | 4.52e-02 | 4.95e-01 | 0.5249 |
| 51594 | NBAS | CCI_3 | Human | Cervix | CC | 4.33e-07 | 6.08e-01 | 0.516 |
| 51594 | NBAS | HTA11_3410_2000001011 | Human | Colorectum | AD | 6.61e-11 | -3.48e-01 | 0.0155 |
| 51594 | NBAS | HTA11_866_2000001011 | Human | Colorectum | AD | 6.98e-04 | -2.37e-01 | -0.1001 |
| 51594 | NBAS | HTA11_8622_2000001021 | Human | Colorectum | SER | 3.17e-03 | -3.23e-01 | 0.0528 |
| 51594 | NBAS | HTA11_10711_2000001011 | Human | Colorectum | AD | 1.37e-03 | -3.27e-01 | 0.0338 |
| 51594 | NBAS | HTA11_7696_3000711011 | Human | Colorectum | AD | 8.51e-03 | -3.11e-01 | 0.0674 |
| 51594 | NBAS | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.12e-02 | -2.61e-01 | 0.294 |
| 51594 | NBAS | HTA11_99999974143_84620 | Human | Colorectum | MSS | 4.27e-04 | -3.30e-01 | 0.3005 |
| 51594 | NBAS | A001-C-207 | Human | Colorectum | FAP | 5.76e-07 | -2.17e-01 | 0.1278 |
| 51594 | NBAS | A015-C-203 | Human | Colorectum | FAP | 2.79e-30 | -3.72e-01 | -0.1294 |
| 51594 | NBAS | A015-C-204 | Human | Colorectum | FAP | 5.83e-11 | -4.14e-01 | -0.0228 |
| 51594 | NBAS | A014-C-040 | Human | Colorectum | FAP | 2.28e-04 | -2.12e-01 | -0.1184 |
| 51594 | NBAS | A002-C-201 | Human | Colorectum | FAP | 9.17e-21 | -3.28e-01 | 0.0324 |
| 51594 | NBAS | A002-C-203 | Human | Colorectum | FAP | 4.24e-02 | -1.44e-01 | 0.2786 |
| 51594 | NBAS | A001-C-119 | Human | Colorectum | FAP | 6.07e-12 | -5.04e-01 | -0.1557 |
| 51594 | NBAS | A001-C-108 | Human | Colorectum | FAP | 4.25e-18 | -2.62e-01 | -0.0272 |
| 51594 | NBAS | A002-C-205 | Human | Colorectum | FAP | 3.10e-29 | -3.82e-01 | -0.1236 |
| 51594 | NBAS | A001-C-104 | Human | Colorectum | FAP | 6.92e-07 | -2.56e-01 | 0.0184 |
| 51594 | NBAS | A015-C-005 | Human | Colorectum | FAP | 5.11e-07 | -2.16e-01 | -0.0336 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003133010 | Cervix | CC | negative regulation of cellular catabolic process | 63/2311 | 262/18723 | 1.10e-07 | 5.68e-06 | 63 |
| GO:00064029 | Cervix | CC | mRNA catabolic process | 56/2311 | 232/18723 | 4.81e-07 | 1.83e-05 | 56 |
| GO:19033119 | Cervix | CC | regulation of mRNA metabolic process | 64/2311 | 288/18723 | 1.71e-06 | 5.64e-05 | 64 |
| GO:000989510 | Cervix | CC | negative regulation of catabolic process | 69/2311 | 320/18723 | 2.15e-06 | 6.55e-05 | 69 |
| GO:00064019 | Cervix | CC | RNA catabolic process | 62/2311 | 278/18723 | 2.18e-06 | 6.56e-05 | 62 |
| GO:00009567 | Cervix | CC | nuclear-transcribed mRNA catabolic process | 30/2311 | 112/18723 | 2.60e-05 | 4.37e-04 | 30 |
| GO:00610139 | Cervix | CC | regulation of mRNA catabolic process | 38/2311 | 166/18723 | 1.07e-04 | 1.36e-03 | 38 |
| GO:00481938 | Cervix | CC | Golgi vesicle transport | 58/2311 | 296/18723 | 2.24e-04 | 2.54e-03 | 58 |
| GO:190331210 | Cervix | CC | negative regulation of mRNA metabolic process | 24/2311 | 92/18723 | 2.49e-04 | 2.77e-03 | 24 |
| GO:00467008 | Cervix | CC | heterocycle catabolic process | 80/2311 | 445/18723 | 3.23e-04 | 3.42e-03 | 80 |
| GO:00346559 | Cervix | CC | nucleobase-containing compound catabolic process | 74/2311 | 407/18723 | 3.77e-04 | 3.88e-03 | 74 |
| GO:00442709 | Cervix | CC | cellular nitrogen compound catabolic process | 79/2311 | 451/18723 | 7.80e-04 | 6.91e-03 | 79 |
| GO:00068907 | Cervix | CC | retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum | 15/2311 | 52/18723 | 1.15e-03 | 9.39e-03 | 15 |
| GO:19023698 | Cervix | CC | negative regulation of RNA catabolic process | 19/2311 | 75/18723 | 1.54e-03 | 1.19e-02 | 19 |
| GO:00194398 | Cervix | CC | aromatic compound catabolic process | 79/2311 | 467/18723 | 2.14e-03 | 1.54e-02 | 79 |
| GO:19013618 | Cervix | CC | organic cyclic compound catabolic process | 80/2311 | 495/18723 | 6.77e-03 | 3.72e-02 | 80 |
| GO:19023738 | Cervix | CC | negative regulation of mRNA catabolic process | 15/2311 | 63/18723 | 8.52e-03 | 4.40e-02 | 15 |
| GO:1903311 | Colorectum | AD | regulation of mRNA metabolic process | 117/3918 | 288/18723 | 1.69e-14 | 4.23e-12 | 117 |
| GO:0009895 | Colorectum | AD | negative regulation of catabolic process | 124/3918 | 320/18723 | 1.66e-13 | 3.35e-11 | 124 |
| GO:0031330 | Colorectum | AD | negative regulation of cellular catabolic process | 104/3918 | 262/18723 | 2.66e-12 | 3.96e-10 | 104 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NBAS | SNV | Missense_Mutation | c.6169N>T | p.Gly2057Trp | p.G2057W | A2RRP1 | protein_coding | deleterious(0.05) | possibly_damaging(0.598) | TCGA-A2-A04U-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| NBAS | SNV | Missense_Mutation | rs758776096 | c.6114G>C | p.Gln2038His | p.Q2038H | A2RRP1 | protein_coding | tolerated(0.24) | benign(0) | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| NBAS | SNV | Missense_Mutation | rs773223545 | c.5830N>A | p.Ala1944Thr | p.A1944T | A2RRP1 | protein_coding | tolerated(0.29) | benign(0.001) | TCGA-A2-A0T0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD |
| NBAS | SNV | Missense_Mutation | novel | c.3172N>A | p.Pro1058Thr | p.P1058T | A2RRP1 | protein_coding | tolerated(0.37) | possibly_damaging(0.899) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
| NBAS | SNV | Missense_Mutation | novel | c.6051N>A | p.Met2017Ile | p.M2017I | A2RRP1 | protein_coding | tolerated(0.08) | benign(0.035) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| NBAS | SNV | Missense_Mutation | c.6094N>A | p.Ser2032Thr | p.S2032T | A2RRP1 | protein_coding | tolerated(0.19) | benign(0.019) | TCGA-AN-A0FY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| NBAS | SNV | Missense_Mutation | c.4618G>A | p.Asp1540Asn | p.D1540N | A2RRP1 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AR-A0TX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| NBAS | SNV | Missense_Mutation | c.1391N>T | p.Gly464Val | p.G464V | A2RRP1 | protein_coding | tolerated(0.12) | benign(0.36) | TCGA-AR-A24W-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | letrozole | SD | |
| NBAS | SNV | Missense_Mutation | c.1018G>A | p.Gly340Arg | p.G340R | A2RRP1 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-C8-A12V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| NBAS | SNV | Missense_Mutation | c.4990N>A | p.Asp1664Asn | p.D1664N | A2RRP1 | protein_coding | tolerated(0.45) | benign(0.003) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |